Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2

3(50.0%)

N/A

2(33.3%)

Phase 4

1(16.7%)

6Total

Phase 2(3)

N/A(2)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT07458529Phase 2Recruiting

Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer

Role: lead

NCT06369584Not ApplicableRecruiting

Prone Position During ECMO in Pediatric Patients With Severe ARDS

Role: lead

NCT05567627Not ApplicableUnknown

Clinical Exploration of Adeno-associated Virus (AAV) Expressing Human Acid Alpha- Glucosidase (GAA) Gene Therapy for Patients With Infantile-onset Pompe Disease

Role: lead

NCT03275415Phase 4Completed

Intratracheal Budesonide/Surfactant Prevents BPD

Role: collaborator

NCT05859984Phase 2Unknown

To Evaluate the Clinical Efficacy and Safety of Recombinant Human Interferon ω Spray in Treatment of Viral Upper Respiratory Tract Infection in Children

Role: lead

NCT05330871Phase 2Unknown

Evaluate the Safety and Immunogenicity of Ad5 COVID-19 Vaccines for Booster Use in Children Aged 6-17 Years.

Role: lead

All 6 trials loaded